Subcutaneous apomorphine and non-motor symptoms in Parkinson's disease

Parkinsonism and Related Disorders

Volumn 19, Issue 12, 2013, Pages 1073-1078

  Todorova, Antoniya ^a   Ray Chaudhuri, K ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Apomorphine; Non motor symptoms; Parkinson's disease

Indexed keywords

APOMORPHINE;

DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; HUMAN; IMPULSIVENESS; INSOMNIA; LONG TERM CARE; MENTAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; PAIN; PARKINSON DISEASE; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; REVIEW; SKIN NODULE; SLEEP; URINARY DYSFUNCTION;

APOMORPHINE; NON MOTOR SYMPTOMS; PARKINSON'S DISEASE;

APOMORPHINE; DOPAMINE AGONISTS; HUMANS; INFUSIONS, SUBCUTANEOUS; PARKINSON DISEASE;

EID: 84889084453     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2013.08.012     Document Type: Review

References (40)

1. Schwab R., Amador L., Lettvin J. Apomorphine in Parkinson's disease. Trans Am Neurol Assoc 1951, 56:251-253.
2. Corsini G.U., Del Zompo M., Gessa G.L., Mangoni A. Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease. Lancet 1979, i:954-956.
3. Hardie R.J., Lees A.J., Stern G.M. On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study. Brain 1984, 107:487-506.
4. Stibe C.M.H., Lees A.J., Kempster P.A., Stern G.M. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1988, i:403-406.
5. Chaudhuri K.R., Critchley P., Abbott R.J., Pye I.F., Millac P.A. Subcutaneous apomorphine for on-off oscillations in Parkinson's disease. Lancet 1988, 2:1260.
6. Katzenschlager R., Hughes A., Evans A., Manson A.J., Hoffman M., Swinn L., et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov Disord 2005, 20:151-157.
7. Martinez-Martin P., Rodriguez-Blazquez C., Kurtis M.M., Chaudhuri K.R., NMS validation group The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov Disord 2011, 26:399-406.
8. Chaudhuri K.R., Healy D., Schapira A.H.V. The non-motor symptoms of Parkinson's disease. Diagnosis and management. Lancet Neurol 2006, 5:235-245.
9. Martinez- Martin P., Rodriguez-Blazquez C., Abe K., Bhattacharyya K.B., Bloem B.R., Carod-Artal F.J., et al. International study on the psychometric attributes of the non-motor symptoms scale in Parkinson's disease. Neurology 2009, 73:1584-1591.
10. Martinez-Martin P., Reddy P., Antonini A., Henriksen T., Katzenschlager R., Odin P., et al. Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson's disease compared to conventional therapy: a real-life study of non-motor effect. JParkinson's Dis 2011, 1:197-203.
11. Reddy P., Martinez-Martin P., Todorova A., Antonini A., Odin P., Martin A., et al. The EuroInf study: a multi-centre European comparative study of apomorphine versus intrajejunal levodopa infusion in a real life cohort of Parkinson's patients. Mov Disord 2013, 28(Suppl.1):S211.
12. Ellis C., Lemmens G., Parkes J.D., Abbott R.J., Pye I.F., Leigh P.N., et al. Use of apomorphine in parkinsonian patients with neurospsychiatric complications of oral treatment. Parkinsonism Relat Disord 1997, 3:103-107.
13. Chaudhuri K.R., Clough C. Subcutaneous apomorphine in Parkinson's diseases. Br Med J 1998, 316:614.
14. Hughes A.J., Bishop S., Kleedorfer B.B., Turjanski N., Fernandez W., Lees A.J., et al. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord 1993, 8:165-170.
15. Chaudhuri K.R., Abbott R.J., Millac P.A.H. Subcutaneous apomorphine for parkinsonian patients with psychiatric side effects on oral treatment. JNeurol Neurosurg Psychiatr 1991, 54:372-373.
16. van Laar T., Postuma A.G., Drent M. Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations. Parkinsonism Relat Disord 2010, 16:71-72.
17. Antonini A., Isaias I.U., Rodolfi G., Landi A., Natuzzi F., Siri C., et al. A5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. JNeurol 2011, 258:579-585.
18. Geerligs L., Meppelink A.M., Brouwer W.H., van Laar T. The effects of apomorphine on visual perception in patients with Parkinson disease and visual hallucinations: a pilot study. Clin Neuropharmacol 2009, 32:266-268.
19. Drapier S., Gillioz A.S., Leray E., Péron J., Rouaud T., Marchand A., et al. Apomorphine infusion in advanced Parkinson's patients with subthalamic stimulation contraindications. Parkinsonism Relat Disord 2012, 18:40-44.
20. Alegret M., Valldeoriola F., Martí M., Pilleri M., Junqué C., Rumià J., et al. Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease. Mov Disord 2004, 19:1463-1469.
21. De Gaspari D., Siri C., Landi A., Cilia R., Bonetti A., Natuzzi F., et al. Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. JNeurol Neurosurg Psychiatr 2006, 77:450-453.
22. Mathers S.E., Kempster P.A., Law P.J., Frankel J.P., Bartram C.I., Lees A.J., et al. Anal sphincter dysfunction in Parkinson's disease. Arch Neurol 1989, 46:1061-1064.
23. Edwards L.L., Quigley E.M., Harned R.K., Hofman R., Pfeiffer R.F. Defecatory function n Parkinson's disease: response to apomorphine. Ann Neurol 1993, 33:490-493.
24. Tison F., Wiart L., Guatterie M., Fouillet N., Lozano V., Henry P., et al. Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson's disease. Mov Disord 1996, 11:729-732.
25. Garcia Ruiz P.J. Nocturnal subcutaneous apomorphine infusion for severe insomnia in Parkinson's disease. Mov Disord 2006, 21:727-728.
26. Reuter I., Ellis C.M., Chaudhuri R.K. Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome. Acta Neurol Scand 1999, 100:163-167.
27. Tribl G.G., Sycha T., Kotzailias N., Zeitlhoger J., Auff E. Apomorphine in idiopathic restless legs syndrome: an exploratory study. JNeurol Neurosurg Psychiatr 2005, 76:181-185.
28. Haba-Rubio J., Staner L., Cornette F., Lainey E., Luthringer R., Krieger J., et al. Acute low single dose of apomorphine reduces periodic limb movements but has no significant effect on sleep arousals: a preliminary report. Neurophysiol Clin 2003, 33:180-184.
29. Priano L., Albani G., Brioschi A., Guastamacchia G., Calderoni S., Lopiano L., et al. Nocturnal anomalous movement reduction and sleep microstructure analysis in parkinsonian patients during 1-night transdermal apomorphine treatment. Neurol Sci 2003, 24:207-208.
30. Factor S., Brown D., Molho E. Subcutaneous apomorphine injections as a treatment for intractable pain in Parkinson's disease. Mov Disord 2000, 15:167-169.
31. Coelho M., Ferreira J., Rosa M., Sampaio C. Treatment options for non-motor symptoms in late-stage Parkinson's. Expert Opin Pharmacother 2008, 9:523-535.
32. Dellapina E., Gerdelat-Mas A., Ory-Magne F., Pourcel L., Galitzky M., Calvas F., et al. Apomorphine effect on pain threshold in Parkinson's disease: a clinical and positron emission tomography study. Mov Disord 2011, 26:153-157.
33. Christmas T.J., Kempster P.A., Chapple C.R., Frankel J.P., Lees A.J., Stern G.M., et al. Role of subcutaneous apomorphine in parkinsonian voiding dysfunction. Lancet 1988, 2:1451-1453.
34. Magennis B., Cashell A., O'Brien D., Lynch T. An audit of apomorphine in the management of complex idiopathic Parkinson's disease in Ireland. Mov Disord 2012, 27(Suppl.1):S44.
35. Todorova A., Martin A., Okai D., Samuel M., Brown R., David A., et al. Assessment of impulse control disorders in Parkinson's patients with infusion therapies: a single centre experience. Mov Disord 2013, 28(Suppl.1):S133.
36. Garcia Ruiz P.J., Sesar Ignacio A., Ares Pensado B., Castro García A., Alonso Frech F., Alvarez López M., et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicentre study. Mov Disord 2008, 23:1130-1136.
37. Manson A.J., Turner K., Lees A.J. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients. Mov Disord 2002, 17:1235-1241.
38. Tyne H.L., Parsons J., Sinnott A., Fox S.H., Fletcher N.A., Steiger M.J. A10 year retrospective audit of long-term apomorphine use in Parkinson's disease. JNeurol 2004, 251:1370-1374.
39. Domperidone: small risk of serious ventricular arrhythmia and sudden cardiac death. Drug Saf Update 2012, 5:A2.
40. Volkmann J., Albanese A., Antonini A., Chaudhuri K.R., Clark C.E., de Bie R.M.A., et al. Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review. JNeurol 2013, 10.1007/s00415-012-6798-6.